Skinner MK. Encyclopedia of reproduction. 2nd ed. Amsterdam: Elsevier/Academic Press; 2018.

Google Scholar 

Ali M, Bariani MV, Vafaei S, et al. Prevention of uterine fibroids: molecular mechanisms and potential clinical application. J Endometr Uterine Disord. 2023;1: 100018.

Article  PubMed  PubMed Central  Google Scholar 

Stewart EA, Laughlin-Tommaso SK, Catherino WH, et al. Uterine fibroids. Nat Rev Dis Primers. 2016;2:16043.

Article  PubMed  Google Scholar 

Marsh EE, Al-Hendy A, Kappus D, et al. Burden, prevalence, and treatment of uterine fibroids: a survey of U.S. women. J Womens Health (Larchmt). 2018;27(11):1359–67.

Article  PubMed  PubMed Central  Google Scholar 

Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90(6):967–73.

Article  CAS  PubMed  Google Scholar 

Catherino WH, Eltoukhi HM, Al-Hendy A. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin Reprod Med. 2013;31(5):370–9.

Article  PubMed  PubMed Central  Google Scholar 

Vannuccini S, Clemenza S, Cassioli E, et al. Uterine fibroids, perceived stress, and menstrual: a key role of heavy menstrual nbleeding. Reprod Sci. 2023;30(5):1608–15.

Article  CAS  PubMed  Google Scholar 

Liu X, Tang J, Luo Y, et al. Comparison of high-intensity focused ultrasound ablation and secondary myomectomy for recurrent symptomatic uterine fibroids following myomectomy: a retrospective study. BJOG. 2020;127(11):1422–8.

Article  CAS  PubMed  Google Scholar 

Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morris JM, Liang A, Fleckenstein K, et al. A systematic review of minimally invasive approaches to uterine fibroid treatment for improving quality of life and fibroid-associated symptoms. Reprod Sci. 2023;30(5):1495–505.

Article  CAS  PubMed  Google Scholar 

Xu F, Deng L, Zhang L, et al. The comparison of myomectomy, UAE and MRgFUS in the treatment of uterine fibroids: a meta analysis. Int J Hyperthermia. 2021;38(2):24–9.

Article  PubMed  Google Scholar 

Cardozo ER, Clark AD, Banks NK, et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(3):211.e1-9.

Article  PubMed  Google Scholar 

Laughlin-Tommaso S, Barnard EP, AbdElmagied AM, et al. FIRSTT study: randomized controlled trial of uterine artery embolization vs focused ultrasound surgery. Am J Obstet Gynecol. 2019;220(2):174.e1-13.

Article  PubMed  Google Scholar 

Yang Q, Ciebiera M, Bariani MV, et al. Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr Rev. 2022;43(4):678–719. https://doi.org/10.1210/endrev/bnab039

Article  PubMed  Google Scholar 

Mas A, Nair S, Laknaur A, et al. Stro-1/CD44 as putative human myometrial and fibroid stem cell markers. Fertil Steril. 2015;104(1):225-34.e3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ono M, Maruyama T, Masuda H, et al. Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci USA. 2007;104(47):18700–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Islam MS, Protic O, Stortoni P, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril. 2013;100(1):178–93.

Article  CAS  PubMed  Google Scholar 

Chegini N. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med. 2010;28(3):180–203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ono M, Yin P, Navarro A, et al. Paracrine activation of WNT/beta-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci USA. 2013;110(42):17053–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ono M, Qiang W, Serna VA, et al. Role of stem cells in human uterine leiomyoma growth. PLoS ONE. 2012;7(5): e36935.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin P, Ono M, Moravek MB, et al. Human uterine leiomyoma stem/progenitor cells expressing CD34 and CD49b initiate tumors in vivo. J Clin Endocrinol Metab. 2015;100(4):E601–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehine M, Kaasinen E, Makinen N, et al. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med. 2013;369(1):43–53.

Article  CAS  PubMed  Google Scholar 

Makinen N, Mehine M, Tolvanen J, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053):252–5.

Article  PubMed  Google Scholar 

Makinen N, Heinonen HR, Moore S, et al. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget. 2011;2(12):966–9.

Article  PubMed  PubMed Central  Google Scholar 

Kampjarvi K, Park MJ, Mehine M, et al. Mutations in exon 1 highlight the role of MED12 in uterine leiomyomas. Hum Mutat. 2014;35(9):1136–41.

Article  PubMed  Google Scholar 

Halder SK, Laknaur A, Miller J, et al. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol Genet Genom. 2015;290(2):505–11.

Article  CAS  Google Scholar 

McGuire MM, Yatsenko A, Hoffner L, et al. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS ONE. 2012;7(3): e33251.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park MJ, Shen H, Kim NH, et al. Mediator kinase disruption in MED12-mutant uterine fibroids from Hispanic women of South Texas. J Clin Endocrinol Metab. 2018;103(11):4283–92.

Article  PubMed  PubMed Central  Google Scholar 

Ulin M, Ali M, Chaudhry ZT, et al. Uterine fibroids in menopause and perimenopause. Menopause. 2020;27(2):238–42.

Article  PubMed  PubMed Central  Google Scholar 

Hummel CW, Geiser AG, Bryant HU, et al. A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats. J Med Chem. 2005;48(22):6772–5.

Article  CAS  PubMed  Google Scholar 

Fuchs-Young R, Howe S, Hale L, et al. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog. 1996;17(3):151–9.

Article  CAS  PubMed  Google Scholar 

Baytur YB, Ozbilgin K, Cilaker S, et al. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2007;135(1):94–103.

Article  CAS  PubMed  Google Scholar 

Lv SL, Wang R, Xue X, et al. Selective estrogen receptor modulator with estrogen does not affect the proliferation and apoptosis of uterine leiomyoma cells. Transl Cancer Res. 2020;9(9):5390–400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lingxia X, Taixiang W, Xiaoyan C. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev. 2007;(2):CD005287.

Lewis TD, Malik M, Britten J, et al. A comprehensive review of the pharmacologic management of uterine leiomyoma. Biomed Res Int. 2018;2018:2414609.

Article  PubMed  PubMed Central  Google Scholar 

Golan A. GnRH analogues in the treatment of uterine fibroids. Hum Reprod. 1996;11(Suppl. 3):33–41.

Article  CAS  PubMed  Google Scholar 

Zhu H, Lai X, Wu J, et al. Meta-study of the clinical effect of conservative treatment in uterine fibroids. J Oncol. 2022;2022:6114287.

Article  PubMed  PubMed Central  Google Scholar 

Dolmans MM, Cacciottola L, Donnez J. Conservative management of uterine fibroid-related heavy menstrual bleeding and infertility: time for a deeper mechanistic understanding and an individualized approach. J Clin Med. 2021;10(19):4389.

Article  CAS  PubMed